# Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

> **NCT00803374** · PHASE1 · WITHDRAWN · sponsor: **Bristol-Myers Squibb**

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** AntiCD137
- **DRUG:** AntiCD137
- **DRUG:** AntiCD137
- **DRUG:** AntiCD137
- **DRUG:** AntiCD137
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT00803374
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-11
- **Primary completion:** 2012-07
- **Final completion:** 2013-01
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2011-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00803374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00803374, "Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00803374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*